Neoleukin Therapeutics, Inc.
NLTXNASDAQHealthcare
$3.49
+$0.05(+1.45%)
Market Cap$8199685
P/E Ratio—
52W High$18.8
52W Low$3.42
Neoleukin Therapeutics, Inc. (NLTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NLTX · earnings · updated Jun 8, 2026
Latest Earnings
Q4 FY2023Report Date: Nov 14, 2023EPS Actual
-$0.41
Est. -$0.80 · +48.8%
Revenue
—
Fiscal Period
Q4 FY2023
FY ends December
Report Date
Nov 14, 2023
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
NLTX reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 14, 2023 | -$0.80 | -$0.41 | +48.8% | — | — | — |
| ▲ Q3 FY2023 | Aug 10, 2023 | -$0.75 | -$0.20 | +73.3% | — | — | — |
| ▼ Q2 FY2023 | May 8, 2023 | -$0.90 | -$1.00 | -11.1% | — | — | — |
| ▼ Q1 FY2023 | Mar 21, 2023 | $0.19 | -$1.20 | -731.6% | — | — | — |
| ▲ Q4 FY2022 | Nov 14, 2022 | -$1.60 | -$1.20 | +25.0% | — | — | — |
| ▲ Q3 FY2022 | Aug 9, 2022 | -$1.50 | -$1.40 | +6.7% | — | — | — |
| ▲ Q2 FY2022 | May 9, 2022 | -$1.50 | -$1.40 | +6.7% | — | — | — |
| ▲ Q1 FY2022 | Mar 1, 2022 | -$1.50 | -$1.40 | +6.7% | $0.00B | — | — |
Q4 FY2023
Nov 14, 2023Beat
EPS Actual
-$0.41
EPS Est.
-$0.80
EPS Surpr.
+48.8%
Revenue
—
Q3 FY2023
Aug 10, 2023Beat
EPS Actual
-$0.20
EPS Est.
-$0.75
EPS Surpr.
+73.3%
Revenue
—
Q2 FY2023
May 8, 2023Miss
EPS Actual
-$1.00
EPS Est.
-$0.90
EPS Surpr.
-11.1%
Revenue
—
Q1 FY2023
Mar 21, 2023Miss
EPS Actual
-$1.20
EPS Est.
$0.19
EPS Surpr.
-731.6%
Revenue
—
Q4 FY2022
Nov 14, 2022Beat
EPS Actual
-$1.20
EPS Est.
-$1.60
EPS Surpr.
+25.0%
Revenue
—
Q3 FY2022
Aug 9, 2022Beat
EPS Actual
-$1.40
EPS Est.
-$1.50
EPS Surpr.
+6.7%
Revenue
—
Q2 FY2022
May 9, 2022Beat
EPS Actual
-$1.40
EPS Est.
-$1.50
EPS Surpr.
+6.7%
Revenue
—
Q1 FY2022
Mar 1, 2022Beat
EPS Actual
-$1.40
EPS Est.
-$1.50
EPS Surpr.
+6.7%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $1.54 | $1.54 | $1.54 | 0 |
| Q2 FY2024 | $1.34 | $1.34 | $1.34 | 0 |
| Q1 FY2024 | $1.58 | $1.58 | $1.58 | 0 |
| Q4 FY2023 | $2.09 | $2.09 | $2.09 | 1 |
| Q3 FY2023 | $-0.15 | $-0.15 | $-0.15 | 0 |
| Q2 FY2023 | $-0.75 | $-0.75 | $-0.75 | 0 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q3 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q1 FY2024 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q3 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
| Q2 FY2023 | $0.0B | $0.0B | $0.0B | 0 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q4 FY2023 | Nov 14, 2023 | +48.8% | $3.36 | $3.50 | +4.17% |
| ▲ Q3 FY2023 | Aug 10, 2023 | +73.3% | $3.20 | $3.16 | -1.25% |
| ▼ Q2 FY2023 | May 8, 2023 | -11.1% | $4.50 | $4.40 | -2.22% |
| ▼ Q1 FY2023 | Mar 21, 2023 | -731.6% | $3.37 | $3.34 | -0.89% |
| ▲ Q4 FY2022 | Nov 14, 2022 | +25.0% | $2.70 | $2.65 | -1.85% |
| ▲ Q3 FY2022 | Aug 9, 2022 | +6.7% | $5.30 | $4.88 | -7.92% |
| ▲ Q2 FY2022 | May 9, 2022 | +6.7% | $6.15 | $5.70 | -7.32% |
| ▲ Q1 FY2022 | Mar 1, 2022 | +6.7% | $12.90 | $12.70 | -1.55% |
Q4 FY2023+4.17%
Report Date
Nov 14, 2023
EPS Beat/Miss
+48.8%
Price Before
$3.36
Price After
$3.50
Q3 FY2023-1.25%
Report Date
Aug 10, 2023
EPS Beat/Miss
+73.3%
Price Before
$3.20
Price After
$3.16
Q2 FY2023-2.22%
Report Date
May 8, 2023
EPS Beat/Miss
-11.1%
Price Before
$4.50
Price After
$4.40
Q1 FY2023-0.89%
Report Date
Mar 21, 2023
EPS Beat/Miss
-731.6%
Price Before
$3.37
Price After
$3.34
Q4 FY2022-1.85%
Report Date
Nov 14, 2022
EPS Beat/Miss
+25.0%
Price Before
$2.70
Price After
$2.65
Q3 FY2022-7.92%
Report Date
Aug 9, 2022
EPS Beat/Miss
+6.7%
Price Before
$5.30
Price After
$4.88
Q2 FY2022-7.32%
Report Date
May 9, 2022
EPS Beat/Miss
+6.7%
Price Before
$6.15
Price After
$5.70
Q1 FY2022-1.55%
Report Date
Mar 1, 2022
EPS Beat/Miss
+6.7%
Price Before
$12.90
Price After
$12.70
Avg Beat Reaction-2.62%
Avg Miss Reaction-1.56%
Beat Rate6 / 8 quarters
Largest Move-7.92% (Q3 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NLTX ends December
Neoleukin Therapeutics, Inc. (NLTX) most recently reported earnings on November 14, 2023 for Q4 FY2023, posting EPS of $-0.41 — beating the analyst consensus of $-0.80 by +48.8%. NLTX has beaten EPS estimates for 2 consecutive quarters. The next NLTX earnings date is expected around September 1, 2026.
Each quarter, investors track NLTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NLTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NLTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NLTX earnings · 5 questionsNeoleukin Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. NLTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NLTX historically reports after market close (AMC).
NLTX earnings datewhen is NLTX earningsNLTX next earnings datewhen does NLTX report earningsNLTX earnings calendar
▸ Source: FMP · Neoleukin Therapeutics, Inc. SEC filings · US GAAP · Neoleukin Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026